BioLineRx (BLRX) News Today $3.56 -0.09 (-2.47%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$3.56 0.00 (0.00%) As of 08/8/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period BioLineRx to Report Second Quarter 2025 Results on August 14, 2025August 7 at 7:00 AM | prnewswire.comH.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025July 4, 2025 | finance.yahoo.comH.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025July 2, 2025 | msn.comBioLineRx Ltd. Approves Key Proposals at Annual MeetingJune 30, 2025 | tipranks.com15 Best Growth Stocks to Invest in for the Next 5 YearsJune 28, 2025 | insidermonkey.com3 Stocks Getting Rare Double Upgrades From Analysts (BLRX)These three stocks have received a rare double upgrade from analysts since their most recent earnings reports; fortunately investors still have time to catch up...June 6, 2025 | marketbeat.comBioLineRx upgraded to Buy from Hold at JonesResearchJune 1, 2025 | finance.yahoo.comSmall Stocks, But Explosive: These 10 Firms Crushed The Market Last WeekMay 31, 2025 | insidermonkey.comJones Trading Upgrades BioLineRx - Depositary Receipt () (BLRX)May 31, 2025 | msn.comBioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ RatingMay 30, 2025 | msn.comWhy Is Nano-Cap BioLineRx Stock Surging On Friday?May 30, 2025 | benzinga.comBioLineRx ADR: Positive Earnings Call Highlights and ChallengesMay 29, 2025 | msn.comBioLineRx Ltd. (NASDAQ:BLRX) Q1 2025 Earnings Call TranscriptMay 28, 2025 | insidermonkey.comBioLineRx Ltd.: BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 28, 2025 | finanznachrichten.deBioLineRx Ltd. Reports Q1 2025 Financial ResultsMay 27, 2025 | tipranks.comBioLineRx Ltd. (BLRX) Q1 2025 Earnings Call TranscriptMay 27, 2025 | seekingalpha.comBioLineRx Reports Q1 2025 Financial Results and Strategic UpdatesMay 27, 2025 | tipranks.comBioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 27, 2025 | prnewswire.comBioLineRx to Report First Quarter 2025 Results on May 27, 2025May 20, 2025 | prnewswire.comBioLineRx Ltd. (BLRX) Stock Price, News, Quote & History - Yahoo FinanceMay 16, 2025 | finance.yahoo.comBioLineRx stock rating cut to Hold at Jones TradingApril 3, 2025 | investing.comBLRX: 2024 Financial ResultsApril 3, 2025 | finance.yahoo.comBioLineRx downgraded to Hold from Buy at JonesResearchApril 2, 2025 | markets.businessinsider.comBioLineRx Ltd. (NASDAQ:BLRX) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comBioLineRx price target adjusted to $26 at H.C. Wainwright after reverse splitApril 1, 2025 | markets.businessinsider.comBioLineRx Ltd. (BLRX) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comBioLineRx Reports 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | prnewswire.comBioLineRx to Report 2024 Annual Results on March 31, 2025March 24, 2025 | prnewswire.comBLRX: Aphexda Transition ProgressingFebruary 19, 2025 | finance.yahoo.comBioLineRx stock hits 52-week low at $3.24 amid sharp declineJanuary 31, 2025 | msn.comBioLineRx trading halted, news pendingJanuary 30, 2025 | markets.businessinsider.comBioLineRx says current cash to provide runway through 2H26January 21, 2025 | markets.businessinsider.comBioLineRx announces strategic shift with licensing dealsJanuary 21, 2025 | msn.comBioLineRx Issues Letter to ShareholdersJanuary 21, 2025 | prnewswire.comBioLineRx Ltd.: BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary SharesJanuary 17, 2025 | finanznachrichten.deBioLineRx changes ratio of ADRs to ordinary sharesJanuary 17, 2025 | markets.businessinsider.comBioLineRx Adjusts ADS Ratio to Maintain Nasdaq ListingJanuary 17, 2025 | tipranks.comBioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary SharesJanuary 17, 2025 | prnewswire.comBioLineRx announces $10M registered direct offeringJanuary 6, 2025 | markets.businessinsider.comBioLineRx Announces $10 Million Registered Direct OfferingJanuary 6, 2025 | prnewswire.comBLRX: Ayrmid Assumes Commercialization EffortsDecember 3, 2024 | finance.yahoo.comBioLineRx Ltd. (NASDAQ:BLRX) Q3 2024 Earnings Call TranscriptNovember 26, 2024 | msn.comBioLineRx Reports Strategic Moves in Q3 2024November 26, 2024 | markets.businessinsider.comBioLineRx Ltd. (BLRX) Q3 2024 Earnings Call TranscriptNovember 25, 2024 | seekingalpha.comBiolineRx Ltd. Announces New Direct Offering of SharesNovember 22, 2024 | markets.businessinsider.comBioLineRx, Ayrmid enter license agreement for motixafortide through Gamida CellNovember 22, 2024 | markets.businessinsider.comBioLineRx Signs A $10mln Upfront Deal With Ayrmid To Commercialise APHEXDANovember 22, 2024 | markets.businessinsider.comBioLineRx inks licensing deal, share purchase agreementNovember 22, 2024 | msn.comBioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.November 21, 2024 | prnewswire.comBioLineRx to Report Third Quarter 2024 Results on November 25, 2024November 20, 2024 | prnewswire.com Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BLRX Media Mentions By Week BLRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLRX News Sentiment▼0.000.48▲Average Medical News Sentiment BLRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLRX Articles This Week▼11▲BLRX Articles Average Week Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OTLK News Today VNRX News Today RPTX News Today IRD News Today CNTX News Today FBRX News Today IZTC News Today APLT News Today INMB News Today BMEA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLRX) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.